Compare Expeditors International of Wshngtn Inc (EXPD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Expeditors International of Wshngtn Inc trades at $192.56 (market cap $25.18B), while State Street SPDR S&P Biotech ETF trades at $153.64 (market cap $10.11B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 2.5× State Street SPDR S&P Biotech ETF's market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EXPD | XBI | |
|---|---|---|
Market Cap | $25.18B | $10.11B |
Volume | 1,003,557 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $194.12 | $169.55 |
52-Week Low | $113.13 | $104.99 |
Typical Hold Time | 43 Days | 38 Days |
Enterprise Value | $24.72B | — |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expeditors International (EXPD) trades at $193.52, up 1.4% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.20. Revenue grew to $11.07B in 2025, while net income held steady at $810M. The company maintains strong profitability with a 42.6% ROE, though valuation multiples like the 28.2 P/E are elevated relative to historical norms.
Outlook is mixed; efficiency initiatives and airfreight demand support growth, but analyst consensus is cautious with a $179.43 price target below the current price. Key risks include reliance on global trade cycles and potential margin pressure. Upside depends on continued earnings beats and sustained freight market strength.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
